Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.51 |
| ▸ | WNT3A | P56704 | 2/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601821 | 0.85 | LMNA (0.54) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL29355245 | 0.85 | CES2 (0.64) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL253276 | 0.85 | CES2 (0.64) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL5158131 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL5163590 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL2914066 | 0.83 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL4306915 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL29740682 | 0.81 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL1360847 | 0.81 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 | |
| SCHEMBL33721999 | 0.81 | CES2 (0.59) | SMN1; SMN2ALDH1A1CES2CES1CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | claimed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | claimed |
| CN-1497048-A | Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative | 拜尔公司 | 2004-05-19 | — | — | CN | claimed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | claimed |
| CN-111004169-B | Synthesis method and application of polysubstituted pyridine derivative | 重庆大学 | 2022-12-23 | — | — | CN | disclosed |
| EP-3268372-B9 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2021-03-31 | — | — | EP | disclosed |
| CN-107548397-B | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200377514-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-12-03 | — | — | US | disclosed |
| US-10822345-B2 | KV1.3 inhibitors and their medical application | 4SC AG (DE) | 2020-11-03 | — | — | US | disclosed |
| US-20200339592-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-10-29 | — | — | US | disclosed |
| US-10723743-B2 | Kv1.3 inhibitors and their medical application | 4SC AG (DE) | 2020-07-28 | — | — | US | disclosed |
| EP-3268372-B1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | disclosed |
| EP-1425010-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-4853027-A | PREEMGENCE, POSTEMERGENCE HOERBICIDES; WEEDS, GRASSES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | SMN1; SMN2 4276/4885ALDH1A1 195/4885CES2 888/4885 |
| US-20200339592-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNA3, KCNN3, KCNK3 | SMN1; SMN2 2222/4885ALDH1A1 3448/4885CES2 3417/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | SMN1; SMN2 3889/4885ALDH1A1 1662/4885CES2 4881/4885 |
| US-10723743-B2 | Kv1.3 inhibitors and their medical application | KCNA3, KCNN3, KCNK3 | SMN1; SMN2 2222/4885ALDH1A1 3448/4885CES2 3417/4885 |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | GRHPR, HPD, HAAO | SMN1; SMN2 4683/4885ALDH1A1 273/4885CES2 441/4885 |
| US-10822345-B2 | KV1.3 inhibitors and their medical application | KCNA3, KCNN3, KCNK3 | SMN1; SMN2 2222/4885ALDH1A1 3448/4885CES2 3417/4885 |
| US-20200377514-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNN3, KCNN2, KCNA3 | SMN1; SMN2 2393/4885ALDH1A1 3178/4885CES2 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.